The early stage of biotech drug development can be a valley of death, but a renewed interest in U.S. federal nondilutive capital and mission driven family offices is quietly revising the investment playbook.

A 2024-2025 analysis of biotechs navigating the funding crunch reported that 38% of seed-stage companies planned to make nondilutive funding a corestrategy. This data aligns with the recent passage of the U.S. budget, allotting substantial financial incentives.

As for family offices, they “are emerging as influential investors in the early-stage life sciences sector,” according to one blog post, citing many U.S. family offices generous capital mandates.  

Robust Nondilutive Funding Opportunities

Nondilutive funding for life sciences companies is a “huge and untapped” market and now is an “incredible time” for the landscape because the long-delayed U.S. federal budget has finally been signed, said Ram May-Ron, managing partner at FreeMind Group. FreeMind specializes in assisting life science organizations secure nondilutive funding from U.S. federal agencies and private foundations to fund R&D.

The budget, approved by President Trump on February 4, increases National Institutes of Health (NIH) funding to roughly $49 billion dollars, nearly doubles the Congressionally Directed Medical Research Programs budget to about $1.3 billion dollars, and funds Advanced Research Projects Agency for Health at $1.5 billion dollars, May-Ron said.

The 2026 budget is the first fully approved U.S. budget since October 2023. Although the original bill faced major cuts, the final allocations granted ultimately represent an industry shift with expanded nondilutive funding, May-Ron added.

The Small Business Innovation Research (SBIR) program, one of the biggest sources of early stage capital for technology commercialization in the U.S., has not yet been reauthorized even though roughly $1.3 billion dollars is already allocated for it in the 2026 budget, he added. This money must be deployed by September 30 once reauthorization occurs.

Still, SBIR is only about 3.2% of the broader federal funding pool. Many other NIH mechanisms have opened further doors for translational, preclinical and clinical research by companies, May-Ron said.

FreeMind collaborates with about 200-300 companies each year to identify the best opportunities and help them submit as many relevant applications as possible. In terms of these company locations, firms in Europe, Australia, Canada and Israel remain eligible and are already receiving NIH support. FreeMind has also built partnerships with non-Chinese Asian pharmas, such as Japanese and Korean companies, to help them identify innovative early stage technologies in the U.S. and Europe developing through the nondilutive funding process.

On the other hand, U.S. federal funding is increasingly tough to attain for China-based or China-connected research.

Ultimately, companies should pursue a unified financing strategy combining venture capital (VC), nondilutive funding and family offices, May-Ron advised.

Keen Family Office Investment Deployment

Family offices are keen to participate in biotech funding opportunities without repeating the mistakes of the “nuclear winter” of the last few years, said Ravi Kiron, managing director of Biopharma Strategy Advisors.

Other factors shaping their investment thesis are transparency on deal structure, return on investment and alignment with the family’s purpose. Many family offices have been established around a connection to a specific disease, often a rare condition, he said, and this trend is unlikely to change.

As the oncology space feels saturated, there is a resurgence of interest in the neuroscience space, enabled by artificial intelligence (AI) and imaging advances that allow for more intricate human brain mapping, Kiron said. As BioSpace previously reported, investment in neuro and CNS innovation shows no signs of slowing.

There is also growing momentum for platform technologies, particularly AI and computational biology, where a reduction in the time and cost of drug development is a key attraction.

Ultimately, founders must have strong science and a compelling narrative about their drug benefit to patient populations and life improvement, Kiron said, while also demonstrating strong team dynamics, execution capability, capital management and a solid IP strategy. In contrast to VCs with numerous junior analysts as gatekeepers, family offices often have investment conversations directly with potential recipients.

Ultimately, Kiron agreed with May-Ron that early stage investing still requires nondilutive financing, family offices and alternative financiers.

You can hear more on this week’s Denatured podcast episode.